Immune Checkpoint Inhibitor Rechallenge and Resumption: a systematic review - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Current Oncology Reports Année : 2022

Immune Checkpoint Inhibitor Rechallenge and Resumption: a systematic review

Résumé

Purpose of the review: The reintroduction of immune checkpoint inhibitors (ICIs) after disease progression (rechallenge) or immune-related adverse events (irAEs) recovering (resumption) raises questions in terms of efficacy and safety. Recent findings: Here, we reviewed literature data about ICIs rechallenge/resumption in cancer patients along with their clinical characteristics to explore those factors associated with better outcomes. Summary: Heterogenous results were pointed out across rechallenge studies with an overall response rate between 0% and 54%, a progression free survival ranged from 1,5 and 12,9 months and an overall survival between 6,5 and 23,8 months. Better outcomes have been recorded in patients with good ECOG PS, longer duration of initial ICI, discontinuation reason of initial ICI other than progression and those who received ICI sequence other than the switch between anti-PD1 and anti-PDL1. Studies about ICI resumption highlighted that certain types of irAEs were more likely to relapse at retreatment. These results suggest that ICI rechallenge / resumption can be an interesting strategy for selected patients.
Fichier principal
Vignette du fichier
Revue ICI-Rechallenge_Resumption_CPlazy.pdf (811 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-04297067 , version 1 (21-11-2023)

Identifiants

Citer

Caroline Plazy, Dalil Hannani, Elisa Gobbini. Immune Checkpoint Inhibitor Rechallenge and Resumption: a systematic review. Current Oncology Reports, 2022, 24 (9), pp.1095-1106. ⟨10.1007/s11912-022-01241-z⟩. ⟨hal-04297067⟩
23 Consultations
91 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More